The Molecular and Translational Allergology (MTA) team focuses on patient-centered research aiming to address and solve unmet medical needs in allergy diagnosis and prevention. The research is performed in close collaboration with other teams at the Department of Infection and Immunity, other LIH departments and technological platforms, as well as with leading clinical and scientific experts at the Centre Hospitalier de Luxembourg, University of Luxembourg, Luxembourg Institute of Science and Technology and a number of clinical and research excellence centers in Europe. 

Our research focuses on: i) allergen molecules, which are key players, both as sensitizers and triggers in allergic reactions; ii) biomarkers identifying early pathological immune reactions to naturally occurring and otherwise harmless substances in air and food. Allergen-based insights and deep immunophenotyping address important aspects of the complex multifactorial puzzle.  

The knowledge around allergens, their molecular and immunological properties, helps to address mechanisms of allergic sensitisation and anaphylaxis, by understanding how allergens enter the human body, cross mucosal epithelia and impact the host microbiome, how they interact with the immune system in order to finally identify advanced biomarkers applicable for the stratification of allergic patients. Inflammatory processes and break of tolerance are the starting points of many allergic diseases manifesting as allergic rhinitis, asthma, atopic dermatitis or food allergy. Unravelling the underlying pathophysiological immune mechanisms of break of tolerance and understanding early life priming of the immune system will ultimately lead to the development of prevention and treatment strategies for allergic diseases.  

Today, the use of single allergens in serum IgE-testing allows deeper insights into the disease cause and course, such as to discriminate between genuine sensitisation and cross-reactivity, as well as to identify potentially mild from severe allergy phenotypes. In addition to serum IgE-typing, the development of new immune biomarkers will allow to identify the patients’ molecular profile and potential responders to available immunotherapies, an important step towards personalised treatment.  

We are closely linked to the clinical practice through our partner, the National Service of Immuno-Allergology at CHL, as well as to a number of clinical and research excellence centres in Europe.